BDTX (Black Diamond Therapeutics) FFO


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price